297 filings
Page 7 of 15
8-K
140 b4kf1flt4
6 Jan 20
Fibrogen Names Enrique Conterno As Chief Executive Officer
5:23pm
8-K
y9jcii15x5fel
23 Dec 19
Fibrogen Submits New Drug Application to the U.S. Fda for Roxadustat In Patients with Anemia of Chronic Kidney Disease
9:06am
UPLOAD
p3n8hgp67ycp4
23 Dec 19
Letter from SEC
12:00am
8-K
cf6ytosmmb6mh9
16 Dec 19
Departure of Directors or Certain Officers
12:00am
CORRESP
57pbdpr 9x505
13 Dec 19
Correspondence with SEC
12:00am
UPLOAD
1gp3rw
3 Dec 19
Letter from SEC
12:00am
8-K
30a8gq 5cv3pabxr2o9i
2 Dec 19
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
7:10am
8-K
v564oec
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
kbh45d
8 Nov 19
Regulation FD Disclosure
2:05pm
8-K
1e73nilj6 1jhotn5db
8 Nov 19
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
2:00pm
8-K
7514ruj9l6r
11 Oct 19
Regulation FD Disclosure
11:49am
8-K
qs24zw0tjcvup5
9 Oct 19
Departure of Directors or Certain Officers
5:14pm
8-K
06eekdgkx 7r
26 Sep 19
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment
9:01am
8-K
zyrly38vd9uu
20 Sep 19
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
9:00am
CT ORDER
8499ffe0hd
4 Sep 19
Confidential treatment order
11:21am
CT ORDER
b0llspfk5ogj7s5yrq
4 Sep 19
Confidential treatment order
11:15am
CT ORDER
gq1 ww1xh
4 Sep 19
Confidential treatment order
11:10am
CT ORDER
xx66vsy2qn0t4zde
4 Sep 19
Confidential treatment order
11:05am
CT ORDER
ij61 ws9nyt02as1
4 Sep 19
Confidential treatment order
10:59am